{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:19:41Z","timestamp":1794745181222,"version":"4.9.1"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014913","name":"Freistaat Sachsen","doi-asserted-by":"publisher","award":["100340676"],"award-info":[{"award-number":["100340676"]}],"id":[{"id":"10.13039\/501100014913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","award":["70115169"],"award-info":[{"award-number":["70115169"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"BMFTR Bonn","doi-asserted-by":"publisher","award":["03ZU2111AB"],"award-info":[{"award-number":["03ZU2111AB"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Te-478\/10-1"],"award-info":[{"award-number":["Te-478\/10-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119947","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:50:40Z","timestamp":1790110240000},"page":"119947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antibody-TLR3 agonist-conjugates program the tumor microenvironment and induce immune responses leading to tumor regression in experimental EGFRvIII-positive glioma"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0756-7081","authenticated-orcid":false,"given":"Alexander","family":"Hagstotz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Schau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5600-3775","authenticated-orcid":false,"given":"Duran","family":"S\u00fcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Buchholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekka","family":"Wehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Schackert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilker","family":"Ey\u00fcpoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Temme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119947_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/imt-2016-0135","article-title":"Tumor-associated macrophages: implications in cancer immunotherapy","volume":"9","author":"Petty","year":"2017","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119947_bib3","article-title":"Immune microenvironment in glioblastoma subtypes","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119947_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01650","article-title":"TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-\u03b1\u03b2 Signaling and Restricts Tumor Progression","volume":"9","author":"Vidyarthi","year":"2018","journal-title":"Front. Immunol."},{"issue":"34","key":"10.1016\/j.biopha.2026.119947_bib5","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.2174\/0929867326666190620103105","article-title":"The next generation of pattern recognition receptor agonists: improving response rates in cancer immunotherapy","volume":"27","author":"DH","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08830185.2010.529976","article-title":"Pathogen recognition by the innate immune system","volume":"30","author":"Kumar","year":"2011","journal-title":"Int. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119947_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.biopha.2026.119947_bib8","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1039\/D2BM00181K","article-title":"Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation","volume":"10","author":"Mills","year":"2022","journal-title":"Biomater. Sci. -Uk"},{"issue":"3","key":"10.1016\/j.biopha.2026.119947_bib9","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1021\/acsnano.7b06995","article-title":"Directing Nanoparticle Biodistribution through Evasion and Exploitation of Stab2-Dependent Nanoparticle Uptake","volume":"12","author":"Campbell","year":"2018","journal-title":"Acs Nano"},{"issue":"23","key":"10.1016\/j.biopha.2026.119947_bib10","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-07-1443","article-title":"First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer","volume":"13","author":"Dudek","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119947_bib11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ajh.23280","article-title":"Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies","volume":"87","author":"Weigel","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119947_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/imt.09.70","article-title":"Toll-like receptor agonists in cancer therapy","volume":"1","author":"Adams","year":"2009","journal-title":"Immunotherapy"},{"issue":"5633","key":"10.1016\/j.biopha.2026.119947_bib13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.biopha.2026.119947_bib14","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.4049\/jimmunol.174.8.4942","article-title":"Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif","volume":"174","author":"Kaiser","year":"2005","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4161\/rna.27717","article-title":"Toward a crystal-clear view of the viral RNA sensing and response by RIG-I-like receptors","volume":"11","author":"Luo","year":"2014","journal-title":"Rna Biol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.addr.2007.12.001","article-title":"Cytoplasmic recognition of RNA","volume":"60","author":"Yoneyama","year":"2008","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2026.119947_bib17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.4049\/jimmunol.1300842","article-title":"A Novel Mitochondrial MAVS\/Caspase-8 Platform Links RNA Virus-Induced Innate Antiviral Signaling to Bax\/Bak-Independent Apoptosis","volume":"192","author":"El Maadidi","year":"2014","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119947_bib18","first-page":"664","article-title":"An Eastern Cooperative Oncology Group Phase -I-Ii Pilot-Study of Polyriboinosinic-Polyribocytidylic Acid Poly-L-Lysine Complex in Patients with Metastatic Malignant-Melanoma","volume":"4","author":"Hawkins","year":"1985","journal-title":"J. Biol. Resp. Modif."},{"issue":"3","key":"10.1016\/j.biopha.2026.119947_bib19","first-page":"599","article-title":"Phase 1-2 Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients with Leukemia or Solid Tumors, Jnci-J Natl Cancer I","volume":"57","author":"Robinson","year":"1976"},{"issue":"2","key":"10.1016\/j.biopha.2026.119947_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11060-008-9705-3","article-title":"A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas","volume":"91","author":"Butowski","year":"2009","journal-title":"J. Neuro-Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119947_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14728222.2013.781585","article-title":"TLR3 agonists and proinflammatory antitumor activities","volume":"17","author":"Sharma","year":"2013","journal-title":"Expert. Opin. Ther. Tar."},{"key":"10.1016\/j.biopha.2026.119947_bib22","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1038\/s41598-019-40032-8","article-title":"Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis","volume":"9","author":"Schau","year":"2019","journal-title":"Sci. Rep. -Uk"},{"issue":"12","key":"10.1016\/j.biopha.2026.119947_bib23","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1158\/2326-6066.CIR-16-0156","article-title":"Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach","volume":"4","author":"Johanns","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"10.1016\/j.biopha.2026.119947_bib24","first-page":"3217","article-title":"Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas","volume":"53","author":"Garcia de Palazzo","year":"1993","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119947_bib25","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1158\/0008-5472.CAN-11-2656","article-title":"Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma","volume":"72","author":"Del Vecchio","year":"2012","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119947_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0165-1110(92)90016-3","article-title":"Amplified cellular oncogenes in neoplasms of the human central nervous system","volume":"276","author":"Fuller","year":"1992","journal-title":"Mutat. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00688850","article-title":"Tumorigenic cell culture lines from a spontaneous VM\/Dk murine astrocytoma (SMA)","volume":"51","author":"Serano","year":"1980","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.biopha.2026.119947_bib28","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J. Immunol. (Baltimore Md. 1950)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119947_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12\/SDF-1alpha-secreting Glioblastoma","volume":"38","author":"Muller","year":"2015","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.biopha.2026.119947_bib30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/2211068213497204","article-title":"Single-cell printer: automated, on demand, and label free","volume":"18","author":"Gross","year":"2013","journal-title":"J. Lab. Autom."},{"issue":"3","key":"10.1016\/j.biopha.2026.119947_bib31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41587-019-0032-3","article-title":"CRISPResso2 provides accurate and rapid genome editing sequence analysis","volume":"37","author":"Clement","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119947_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201700072","article-title":"A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA","author":"Tietze","year":"2017","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib33","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2026.119947_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202249923","article-title":"Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methods","volume":"53","author":"Bayerl","year":"2023","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"16","key":"10.1016\/j.biopha.2026.119947_bib36","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","article-title":"RSeQC: quality control of RNA-seq experiments","volume":"28","author":"Wang","year":"2012","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib37","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. B"},{"issue":"43","key":"10.1016\/j.biopha.2026.119947_bib40","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.biopha.2026.119947_bib41","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/neuonc\/nor098","article-title":"RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo","volume":"13","author":"Hendruschk","year":"2011","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119947_bib42","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Antunes","year":"2021","journal-title":"Nat. Neurosci."},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/cdd.2015.176","article-title":"Inflammasome-dependent IL-1beta release depends upon membrane permeabilisation","volume":"23","author":"Martin-Sanchez","year":"2016","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.biopha.2026.119947_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8515","article-title":"Caspase-8 scaffolding function and MLKL regulate NLRP3 inflammasome activation downstream of TLR3","volume":"6","author":"Kang","year":"2015","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2026.119947_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1407899","article-title":"Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade","volume":"7","author":"De Waele","year":"2018","journal-title":"Oncoimmunology"},{"issue":"10","key":"10.1016\/j.biopha.2026.119947_bib46","doi-asserted-by":"crossref","first-page":"6720","DOI":"10.4049\/jimmunol.181.10.6720","article-title":"TLR ligands in the local treatment of established intracerebral murine gliomas","volume":"181","author":"Grauer","year":"2008","journal-title":"J. Immunol."},{"issue":"7718","key":"10.1016\/j.biopha.2026.119947_bib47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biopha.2026.119947_bib48","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1073\/pnas.1519657113","article-title":"Activation of RNase L is dependent on OAS3 expression during infection with diverse human viruses","volume":"113","author":"Li","year":"2016","journal-title":"P Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.biopha.2026.119947_bib49","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.4049\/jimmunol.0900557","article-title":"The Nucleotide-Binding Oligomerization Domain-Like Receptor NLRC5 Is Involved in IFN-Dependent Antiviral Immune Responses","volume":"184","author":"Kuenzel","year":"2010","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond","volume":"16","author":"Perng","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib51","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1084\/jem.20080570","article-title":"An MHC class Ib-restricted CD8 T cell response confers antiviral immunity","volume":"205","author":"Swanson","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2026.119947_bib52","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","article-title":"Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment","volume":"95","author":"Hobbs","year":"1998","journal-title":"P Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.biopha.2026.119947_bib53","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119947_bib54","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.nantod.2015.06.006","article-title":"Nanoparticle uptake: The phagocyte problem","volume":"10","author":"Gustafson","year":"2015","journal-title":"Nano Today"},{"key":"10.1016\/j.biopha.2026.119947_bib55","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-12-417028-5.00006-5","article-title":"Macrophage activation and polarization as an adaptive component of innate immunity","volume":"120","author":"Locati","year":"2013","journal-title":"Adv. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119947_bib56","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4049\/jimmunol.1900791","article-title":"A mitochondrial micropeptide is required for activation of the Nlrp3 inflammasome","volume":"204","author":"Bhatta","year":"2020","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119947_bib57","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/neuonc\/nop047","article-title":"Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study","volume":"12","author":"Carpentier","year":"2010","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119947_bib58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1215\/15228517-2008-012","article-title":"Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors","volume":"10","author":"Sampson","year":"2008","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib59","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2006.08.1117","article-title":"Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group","volume":"25","author":"Kunwar","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib60","article-title":"Convection-enhanced delivery of immunomodulatory therapy for high-grade glioma","volume":"5","author":"Sperring","year":"2023","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.biopha.2026.119947_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/283649","article-title":"Activation of dendritic cells by the novel Toll-like receptor 3 agonist RGC100","volume":"2013","author":"Naumann","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib62","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1038\/s41598-023-31198-3","article-title":"Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim elicits strong antibody and T-cell responses in mice","volume":"13","author":"Horvath","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib63","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/s41467-021-23244-3","article-title":"PLGA-particle vaccine carrying TLR3\/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy","volume":"12","author":"Koerner","year":"2021","journal-title":"Nat. Commun."},{"issue":"52","key":"10.1016\/j.biopha.2026.119947_bib64","doi-asserted-by":"crossref","first-page":"13655","DOI":"10.1073\/pnas.1714587115","article-title":"PSMA-targeted polyinosine\/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice","volume":"114","author":"Langut","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.biopha.2026.119947_bib65","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2326-6066.CIR-15-0203","article-title":"HER2-targeted polyinosine\/polycytosine therapy inhibits tumor growth and modulates the tumor immune microenvironment","volume":"4","author":"Zigler","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119947_bib66","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/bc500252a","article-title":"Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery","volume":"25","author":"Joubran","year":"2014","journal-title":"Bioconjug Chem."},{"issue":"5","key":"10.1016\/j.biopha.2026.119947_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13050676","article-title":"Targeted RNAi of BIRC5\/survivin using antibody-conjugated poly(Propylene Imine)-based polyplexes inhibits growth of PSCA-positive tumors","volume":"13","author":"Jugel","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6857","key":"10.1016\/j.biopha.2026.119947_bib68","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/neuonc\/nor182","article-title":"Microglia isolated from patients with glioma gain antitumor activities on poly (I:C) stimulation","volume":"14","author":"Kees","year":"2012","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41423-023-01110-0","article-title":"Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment","volume":"21","author":"Zheng","year":"2024","journal-title":"Cell. & Mol. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119947_bib71","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41419-018-0850-0","article-title":"Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis","volume":"9","author":"Alkurdi","year":"2018","journal-title":"Cell. Death Dis."},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib72","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1158\/0008-5472.CAN-09-1162","article-title":"Toll-like Receptor 3-Mediated Suppression of TRAMP Prostate Cancer Shows the Critical Role of Type I Interferons in Tumor Immune Surveillance","volume":"70","author":"Chin","year":"2010","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119947_bib73","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.4049\/jimmunol.1103811","article-title":"Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer","volume":"188","author":"Forte","year":"2012","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119947_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2227510","article-title":"A chemically defined TLR3 agonist with anticancer activity","volume":"12","author":"Le Naour","year":"2023","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2026.119947_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1026954","article-title":"Major pathways involved in macrophage polarization in cancer","volume":"13","author":"Kerneur","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119947_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00161","article-title":"Cancer: a tale of aberrant PRR response","volume":"5","author":"Nagi","year":"2014","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119947_bib77","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/neuonc\/nou324","article-title":"Glioma-derived versican promotes tumor expansion via glioma-associated microglial\/macrophages Toll-like receptor 2 signaling","volume":"17","author":"Hu","year":"2015","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119947_bib78","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41590-023-01526-w","article-title":"Molecular mechanisms of gasdermin D pore-forming activity","volume":"24","author":"Devant","year":"2023","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119947_bib79","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ni978","article-title":"Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon","volume":"4","author":"Le Bon","year":"2003","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119947_bib80","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nm0497-414","article-title":"Mac-1 (CDllb\/CD18) is an oligodeoxynucleotide-binding protein","volume":"3","author":"Benimetskaya","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2026.119947_bib81","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7280","article-title":"Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo","volume":"6","author":"Matsumoto","year":"2015","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.biopha.2026.119947_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15245752","article-title":"The defined TLR3 agonist, nexavant, exhibits anti-cancer efficacy and potentiates anti-PD-1 antibody therapy by enhancing immune cell infiltration","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:00:21Z","timestamp":1794744021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":82,"alternative-id":["S0753332226009832"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119947","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-TLR3 agonist-conjugates program the tumor microenvironment and induce immune responses leading to tumor regression in experimental EGFRvIII-positive glioma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119947"}}